Document:

Document

FIRST AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT
THIS FIRST AMENDMENT TO REVOLVING CREDIT LOAN AGREEMENT (this “Amendment”) is entered into as of August 14, 2018, by and between CUMBERLAND PHARMACEUTICALS INC., a Tennessee corporation (the “Borrower”), and PINNACLE BANK, a Tennessee banking corporation (the “Lender”).
RECITALS:
A.The Borrower and the Lender entered into that certain Revolving Credit Loan Agreement (the “Loan Agreement”) dated as of July 31, 2017. Capitalized terms not otherwise defined therein have the same meaning as set forth in the Loan Agreement.
B. The Borrower and the Lender desire to amend the Loan Agreement as provided herein.
NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows:
1. Section 6.7 of the Loan Agreement is hereby amended and restated as follows: 
6.7 Funded Debt Ratio and Tangible Capital Ratio. Permit both (i) the Funded Debt Ratio of the Borrower as calculated for the Borrower and its Subsidiaries at the end of each fiscal quarter on a rolling four quarter basis to exceed 2.50 to 1.00, and (ii) the Funded Debt to Tangible Capital Ratio of the Borrower as calculated for the Borrower and its Subsidiaries to exceed forty percent (40%).  For clarification, if the Borrower maintains compliance with either of the above required calculations, then the Borrower shall be in compliance with this Section 6.7 for the applicable period.
2. The following new definitions are hereby added to Section 9.1 of the Loan Agreement: 
“Funded Debt to Tangible Capital Ratio” means the ratio, expressed as a percentage, of Funded Debt divided by Tangible Capital. 
“Tangible Capital” means the amount equal to total shareholders’ equity, plus Funded Debt, less the value of intangible assets, all of the foregoing to be determined in accordance with the financial statements and reports provided to Lender, which are to be prepared in accordance with GAAP. 
3. The Loan Agreement is not amended in any other respect.
4. The Borrower reaffirms the terms and provisions of the Loan Agreement, along with the other Loan Documents, and the Borrower agrees that such terms and provisions are valid and binding, enforceable in accordance with its terms and provisions, subject to no defense, counterclaim, or objection.
[signatures commence on following page]

ENTERED INTO as of the date first written above.
						
	BORROWER: 
 
CUMBERLAND PHARMACEUTICALS INC. 
 

	
	By:
	/s/ A.J. Kazimi

A.J. Kazimi, 
Chairman and Chief Executive Officer
 

						
	LENDER: 
 
PINNACLE BANK 
 

	
	By:
	/s/ Tim Bewley

Tim Bewley,
Senior Vice President

[Signature Page to First Amendment to Revolving Credit Loan Agreement]Exhibit 10.1

 

Amendment
No. 1

to

RESTATED CONSULTING AGREEMENT

 

This
Amendment No. 1 (the “Amendment”) to Restated Consulting Agreement dated April 29, 2018 (the “Original Agreement”)
is effective November 7, 2018 (the “Amendment Effective Date”) and is by and among Wize Pharma Ltd. (Registration
Number 520033259), a limited liability company operating under the laws of Israel with offices at Hanagar 24, PO Box 6653 Hod
Hasharon, Israel (the “Company”) and N. Danenberg Holdings (2000) Ltd. (Registration Number 512950981), a limited
liability company operating under the laws of Israel having its principal place of business at Borochov 4, Hod- Hasharon, (the
“Consulting Company”) through Noam Danenberg I.D. 27868272, an individual residing at Borochov 4, Hod Hasharon (“Mr.
Danenberg”).

 

WHEREAS:

 

	A.     	As of the Amendment Effective Date, Mr. Danenberg has resigned as Chief Operating Officer of the Company’s sole stockholder, Wize Pharma, Inc. (“Wize”) and has been elected to the Board of Directors of Wize (the “Board”) and appointed Chairman of the Board;
	 	 
	B.      	The Parties desire to amend the Original Agreement accordingly; and
	 	 
	C.     	Except as set forth in this Amendment, all other terms and conditions of the Original Agreement shall remain in full force and effect.

 

WHEREFORE,
IT IS HEREBY AGREED as follows:

 

1. 
The second and third paragraphs of Section 1.1 of the Original Agreement shall be amended and restated in their entirety as set
forth below:

 

In
this regard, the Consulting Company through Mr. Danenberg exclusively shall provide the Company and any of its Affiliates with
general strategic consulting services, as required in the field of business development and raising funds, all as shall be required
from time to time by the Company (the “Consulting Services” or the “Services”).

 

While
acting as a representative of Consulting Company, Mr. Danenberg shall report to and receive instructions from the Board of Directors
of the Company from time to time.

 

2.  
Except as set forth in this Amendment, all other terms and conditions of the Original Agreement shall remain in full force and
effect.

 

[signature
page follows immediately]

 

     

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed the Agreement effective as of the date first above written.

 

	COMPANY:	 	 	 
	 	 	 	 	 
	WIZE PHARMA LTD.	 	 	 
	 	 	 	 	 
	Signature:  	/s/ Yossi Keret	 	Signature: 	/s/
    Or Eisenberg
	Name: 	Yossi Keret	 	Name: 	Or Eisenberg
	Title: 	Director	 	Title: 	Director

 

	CONSULTING PARTIES:	 
	 	 	 
	N. DANENBERG HOLDINGS (2000)
    LTD.	 
	 	 	 
	Signature:  	/s/
    Noam Danenberg	 
	Name: 	Noam Danenberg	 
	Title:	 	 
	 	 	 
	Signature: 	 /s/
    Noam Danenberg	 
	Name: 	Noam Danenberg, in his	 
	 	Individual capacityExhibit 10.2

 

CONSULTING AGREEMENT

 

This
Consulting Agreement (this “Agreement”) is dated as of November 7, 2018, by and between WIZE PHARMA INC
and/or WIZE PHARMA, LTD. (“Company”), with a principal place of business and mailing address at
24 Hanagar st. PO Box 6653, Hod Hasharon, Israel; and Ron Med Ltd, an Israeli company (“Consultant”),
with address for notices at: 22a HaOranim St. Hod Hasharon, Israel.

 

WHEREAS, the Company
wishes to obtain from the Consultant the Services pursuant to the terms and conditions of this Agreement; and

 

WHEREAS, the Consultant
wishes to provide the Company with the Services pursuant to the terms and conditions of this Agreement;

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and legal sufficiency of which is hereby acknowledged, the parties
hereto hereby agree as follows:

 

1. The Services.
During the term of this Agreement, the Consultant agrees, when requested by the Company, to act as a consultant and render to the
Company the services set forth in Exhibit A hereto (the “Services”).

 

2. Supervision.
While acting as a consultant for the Company, the Consultant shall be under the supervision of the Company’s CEO (or a person
designated thereby).

 

3. Term. The contractual
relationship pursuant to this Agreement will commence on the date hereof (“Commencement Date”) and shall expire
no less than one year and shall be renewed for additional one year periods. Notwithstanding the foregoing, each party may, only
after one year following the Commencement Date, terminate this Agreement (A) upon 60 days prior written notice or (B) immediately
by provision of a written notice, in any of the following circumstances: (i) in the case of Company - commission of a criminal
offence, breach of trust or similar action committed by Consultant adverse to the Company; (ii) in the case of Company –
material breach of any of the Consultant’s undertakings as set forth in this Agreement; or (iii) in the case of Consultant
– material breach of any of the Company’s undertakings as set forth in this Agreement.

 

4. Compensation
– The Consultant shall be entitled to receive consideration for the Services as set forth in Exhibit A hereto. The
consideration payable (including issued) hereunder includes all taxes, levies and charges however designated and levied by any
state, local, or government agency (including VAT). Consultant shall have sole responsibility for the payment of all of such taxes,
levies and charges and Company may deduct and withhold from any consideration made hereunder all sums which it is required to deduct
or withhold pursuant to any applicable laws.

 

5. Confidentiality
and Intellectual Property Rights.

 

5.1 The Consultant
agrees during the term of this Agreement and thereafter that it will hold the Proprietary Information of the Company (for purposes
hereof, including any of its affiliates) in confidence and will not use Proprietary Information in any manner or for any purpose
other than providing the Company with the Services. By way of illustration but not limitation, “Proprietary Information”
includes (a) trade secrets, inventions, mask works, ideas, processes, formulas, source and object codes, data, programs, other
works of authorship, know-how, improvements, discoveries, developments, designs and techniques; and (b) information regarding
plans for research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements,
licenses, prices and costs, suppliers and customers; and (c) information regarding the skills and compensation of other employees
of Company.

 

    	 	1	 

     

    

 

5.2 The Consultant
understands that Company has received and will in the future receive from third parties confidential or proprietary information
(“Third Party Information”). Consultant agrees to hold Third Party Information in confidence and not to disclose
to anyone (other than Company personnel who need to know such information in connection with their work for the Company) or to
use, except in connection with Consultant provision of Services for Company, Third Party Information unless authorized in writing
by the Company.

 

5.3 Consultant irrevocably
assigns to Company all right, title and interest worldwide in and to the Company Work Product and all applicable intellectual property
rights related to the Company Work Product and agrees not to challenge the validity of Company’s ownership in the Company
Work Product. As used in this Agreement, the term “Company Work Product” means any Proprietary Information that
is solely or jointly conceived, made, reduced to practice, or learned by Consultant in the course of any provision of Services.

 

5.4 Consultant agrees
to cooperate with Company or its designee(s), both during and after the termination of this Agreement, to carry out the purpose
of this Section 5.

 

5.5 Upon termination
of the Agreement or earlier as requested by Company, Consultant will deliver to Company any and all material containing any Company
Work Product, Third Party Information or Proprietary Information of Company.

 

6. Representations
and Warranties. Consultant hereby represents and warrants and acknowledges (i)
that Consultant has full right and power to enter into and perform this Agreement in good faith without the consent of any third
party; (ii) that during the term of this Agreement not to accept any work or enter into any contract or understanding or accept
an obligation, inconsistent with Consultant’s obligations under this Agreement or the scope of the Services; Data and software
stored on magnetic and other media that cannot be returned shall be destroyed by Consultant together with all copies thereof; and
(iii) in connection with the stock options exercisable inot shares of common stock of the Company issuable hereunder as consideration,
Consultant understands that the investment in such securities is speculative in nature and involves a high degree of risk, and
she or he is able to bear the economic risks of an investment therein.

 

7. Independent Consultant Relationship;
Etc. Consultant’s relationship with Company will be that of an independent consultant and nothing in this Agreement should
be construed to create a partnership, joint venture, or employer-employee relationship. Consultant is not the agent of Company
and is not authorized to make any representation, contract, or commitment on behalf of Company. Consultant will not be entitled
to any of the benefits that Company may make available to its employees, such as group insurance, profit-sharing, or retirement
benefits.

 

8. General Provisions.

 

8.1 Severability.
In case any one or more of the provisions contained in this Agreement shall, for any reason, be held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement,
and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. If
moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as
to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable
to the extent compatible with the applicable law as it shall then appear.

 

    	 	2	 

     

    

 

8.2 Governing Law;
Venue.

 

8.2.1 This Agreement,
including the validity, interpretation, or performance of this Agreement and any of its terms or provisions, and the rights and
obligations of the parties under this Agreement shall be exclusively governed by, construed and interpreted in accordance with
the laws of the State of Israel, without regards to the choice of law provisions thereof.

 

8.2.2 In the event
of any dispute or claim in connection with this Agreement, then either party may submit the dispute or claim to (and all such disputes
and claims shall be resolved solely by) the competent courts in Tel Aviv, Israel.

 

8.2.3 Each of the
parties further agrees that notice as provided in Section 8.6 hereof shall, without derogating from any other proper means of serving
process under applicable law, constitute sufficient service of process and the parties further waive any argument that such service
is insufficient.

 

8.3 No Assignment.
This Agreement may not be assigned by the Consultant without Company’s prior and written consent, and any such attempted
assignment shall be void and of no effect.

 

8.4 Waiver. No
waiver by Company of any breach of this Agreement shall be a waiver of any preceding or succeeding breach. No waiver by Company
of any right under this Agreement shall be construed as a waiver of any other right.

 

8.5 Entire Agreement.
This Agreement, including Exhibit A hereto, is the final, complete and exclusive agreement of the parties with respect to the subject
matter hereof and supersedes and merges all prior discussions between us. No modification of or amendment to this Agreement, nor
any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged

 

8.6 Notices. All
communications under this Agreement shall be in writing and shall be delivered by hand, facsimile or mailed by registered or certified
mail, postage prepaid, or electronic email to the address of such party in the preamble to this Agreement or at such other address
as such party may have furnished to the other party in writing. Any notice so addressed shall be deemed to be given: if delivered
by hand or by facsimile or email, on the first business day following the date of such delivery; if mailed by courier, on the first
business day following the date of such mailing; and if mailed by registered or certified mail, on the third business day after
the date of such mailing.

 

8.7 Survival.
The following provisions shall survive in good faith for 24 month termination of this Agreement: Sections 3, 5, 6, 7 and 8.

 

8.8 Section Headings.
The headings of the sections and subsections of this Agreement are inserted for convenience only and shall not be deemed to constitute
a part thereof.

 

8.9 Construction.
The words “hereof,” “herein,” and “hereunder” and words of similar import, when used in this
Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The use of the word
“or” shall not be exclusive unless expressly indicated otherwise. Any reference to “days” means calendar
days unless Business Days are expressly specified. The word “party” shall, unless the context otherwise requires, be
construed to mean a party to this Agreement. Any reference to a party to this Agreement or any other agreement or document contemplated
hereby shall include such party’s successors and permitted assigns. The headings herein are for convenience of reference
only, do not constitute part of this Agreement, and shall not be deemed to limit or otherwise affect any of the provisions hereof.
All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as
if set forth in full herein. Whenever the words “include,” “includes” or “including” are used
in this Agreement, they shall be deemed to be followed by the words “without limitation.” The parties hereto agree
that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be applied
in the construction or interpretation of this Agreement.

  

[signature page follows]

 

    	 	3	 

     

    

 

IN WITNESS WHEREOF, the parties have executed this Consulting
Agreement on the date first written above.

 

	Ron Med Ltd	 
	 	 
	By: 	/s/ Ron Mayron	 
	Name: 	Ron Mayron	 
	Title:	 	 
	 	 
	WIZE PHARMA, INC.	 
	 	 
	By: 	/s/ Or Eisenberg	 
	Name:  	Or Eisenberg	 
	Title: 	Acting CEO	 
	 	 
	WIZE PHARMA, LTD.	 
	 	 
	By: 	/s/ Or Eisenberg	 
	Name: 	Or Eisenberg	 
	Title: 	Director	 

 

    	 	4	 

     

    

 

EXHIBIT A

SERVICES AND CONSIDERATION

 

		-	Position: Strategic advisor to the Company’s senior management and Board of Directors

  

		-	Scope: Expected to be available for strategic meetings/sessions/calls with management on a weekly
basis and for all board of directors or relevant committee meetings

  

		-	Compensation: NIS 20,000 (including VAT if applicable) per full month (“the monthly payment”),
against a tax invoice in accordance with the law which the Consultant shall submit to the Company. The monthly payment shall be
paid by the Company (either Wize Pharma Inc. or Wize Pharma Ltd., at Company’s discretion) not later than 10 days from the date
of issue of an undisputed tax invoice. The Consultant undertakess to submit the tax invoices to the Company not later than the
5th day of each calendar month for the preceding month.

  

		-	Consultant will not be reimbursed for any expenses incurred in connection with the performance
of the Services, unless otherwise agreed in writing by the Company and in advance.

 

    	 	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]